{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-253478","form_type":"8-K","ticker":"TSHA","cik":"0001806310","company_name":"Taysha Gene Therapies, Inc.","filed_at":"2026-06-02T20:05:28+00:00","discovered_at":"2026-06-02T20:07:00.596069+00:00","generated_at":"2026-06-02T20:12:51.252942+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Taysha Gene Therapies annual meeting elects directors, ratifies auditor, approves say-on-pay","bullets":["Shareholders elected Sean P. Nolan (169.1M for) and Laura Sepp-Lorenzino (150.1M for) as directors until 2029.","Deloitte & Touche ratified as independent auditor for FY2026 with 243.8M votes for.","Non-binding advisory vote on named executive officer compensation approved: 168.1M for vs 36.4M against.","Advisory vote on frequency of say-on-pay: annual basis chosen with 203.8M votes for one year.","Approximately 84.86% of outstanding shares were represented at the meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-253478","json":"https://secwatch.observer/filing/0001193125-26-253478.json","markdown":"https://secwatch.observer/filing/0001193125-26-253478.md","text":"https://secwatch.observer/filing/0001193125-26-253478.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1806310/000119312526253478/0001193125-26-253478-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1806310/000119312526253478/d159199d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T20:12:51.252942+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0a268124772ae38110ab5d44e4f9277461c07a6e","claim":"Taysha Gene Therapies, Inc. shareholders approved Approval of, on a non-binding advisory basis, the compensation of the Company's named executive officers at the 2026-06-01 meeting.","evidence_excerpt":"Proposal No. 3 : Approval of, on a non-binding advisory basis, the compensation of the Company’s named executive officers, as disclosed in the proxy statement. The votes were cast as follows: Votes For Votes Against Abstained Approval of the compensation of the Company’s named executive officers 168,142,551 36,396,784 345,291 Broker Non-Votes: 38,973,186","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1806310/000119312526253478/0001193125-26-253478-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-01"}],"fact_type":"shareholder_vote"},{"claim_id":"1eed4de4f6eacec294e26aa0ca83c4464dfb2599","claim":"Taysha Gene Therapies, Inc. shareholders approved Indication of, on a non-binding advisory basis, the preferred frequency of future stockholder advisory votes on the compensation of the Company's named executive officers at the 2026-06-01 meeting.","evidence_excerpt":"Proposal No. 4 : Indication of, on a non-binding advisory basis, the preferred frequency of future stockholder advisory votes on the compensation of the Company’s named executive officers. The votes were cast as follows: One Year Two Years Three Years Abstained Advisory indication of preferred frequency of future shareholder advisory votes on Company’s named executive officer compensation 203,825,717 360,924 630,378 67,607 Broker Non-Votes: 38,973,186","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1806310/000119312526253478/0001193125-26-253478-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay frequency"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-01"}],"fact_type":"shareholder_vote"},{"claim_id":"2a127d8c780bd836f4855fa63b720bf4b29e5f11","claim":"Taysha Gene Therapies, Inc. shareholders approved Election of two nominees to serve as directors until the 2029 annual meeting at the 2026-06-01 meeting.","evidence_excerpt":"Proposal No. 1 : Election of two nominees to serve as directors until the 2029 annual meeting of stockholders and until their respective successors are elected and qualified. The votes were cast as follows: Name Votes For Votes Withheld Sean P. Nolan 169,142,295 35,742,331 Laura Sepp-Lorenzino, Ph.D. 150,094,517 54,790,109 Broker Non-Votes: 38,973,186 Both nominees were elected.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1806310/000119312526253478/0001193125-26-253478-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-01"}],"fact_type":"shareholder_vote"},{"claim_id":"66cc74049d08d00d4bf3a31ef8c20382cd6e80da","claim":"Taysha Gene Therapies, Inc. shareholders approved Ratification of the selection of Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-06-01 meeting.","evidence_excerpt":"Proposal No. 2 : Ratification of the selection of Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. The votes were cast as follows: Votes For Votes Against Abstained Ratification of selection of Deloitte & Touche LLP 243,814,085 25,551 18,176 Broker Non-Votes: 0","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1806310/000119312526253478/0001193125-26-253478-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-01"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}